FDx Advisors’s Novo Nordisk NVO Stock Holding History

FDx Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,017	Closed	-$306K	–	186
2025 Q4	$306K	Buy	6,017 +298	+5%	+$15.2K	0.16%	66
2025 Q3	$283K	Sell	5,719 -771	-12%	-$45.1K	0.08%	136
2025 Q2	$448K	Sell	6,490 -3,802	-37%	-$259K	0.14%	99
2025 Q1	$715K	Sell	10,292 -1,541	-13%	-$127K	0.23%	70
2024 Q4	$1.02M	Buy	11,833 +1,655	+16%	+$179K	0.3%	59
2024 Q3	$1.21M	Sell	10,178 -458	-4%	-$61.1K	0.33%	63
2024 Q2	$1.52M	Sell	10,636 -29,046	-73%	-$3.85M	0.42%	50
2024 Q1	$5.09M	Sell	39,682 -19,680	-33%	-$2.34M	0.77%	29
2023 Q4	$6.14M	Buy	59,362 +8,870	+18%	+$877K	0.47%	47
2023 Q3	$4.59M	Sell	50,492 -17,028	-25%	-$1.5M	0.38%	71
2023 Q2	$5.46M	Buy	67,520 +6,052	+10%	+$494K	0.3%	89
2023 Q1	$4.16M	Hold	61,468	–	–	0.18%	122
2022 Q4	$4.16M	Sell	61,468 -7,778	-11%	-$456K	0.18%	122
2022 Q3	$3.45M	Sell	69,246 -24,278	-26%	-$1.3M	0.15%	132
2022 Q2	$5.21M	Sell	93,524 -30,776	-25%	-$1.71M	0.2%	112
2022 Q1	$6.9M	Buy	124,300 +5,382	+5%	+$276K	0.23%	89
2021 Q4	$6.66M	Buy	118,918 +6,956	+6%	+$377K	0.18%	106
2021 Q3	$5.38M	Buy	111,962 +3,968	+4%	+$192K	0.17%	108
2021 Q2	$4.52M	Buy	107,994 +14,120	+15%	+$547K	0.15%	124
2021 Q1	$3.16M	Buy	93,874 +1,898	+2%	+$67.6K	0.12%	136
2020 Q4	$3.21M	Buy	91,976 +6,874	+8%	+$238K	0.13%	134
2020 Q3	$2.95M	Sell	85,102 -6,690	-7%	-$223K	0.14%	122
2020 Q2	$3M	Sell	91,792 -4,170	-4%	-$133K	0.16%	117
2020 Q1	$2.89M	Buy	95,962 +3,652	+4%	+$109K	0.19%	105
2019 Q4	$2.67M	Buy	92,310 +10,680	+13%	+$296K	0.15%	125
2019 Q3	$2.11M	Buy	81,630 +6,730	+9%	+$170K	0.15%	122
2019 Q2	$1.91M	Buy	74,900 +66,542	+796%	+$1.64M	0.07%	199
2019 Q1	$219K	Buy	+8,358	New	+$205K	0.01%	705
2018 Q4	–	Sell	-12,006	Closed	-$283K	–	734
2018 Q3	$283K	Sell	12,006 -3,490	-23%	-$85.2K	0.01%	714
2018 Q2	$357K	Sell	15,496 -15,688	-50%	-$373K	0.01%	659
2018 Q1	$768K	Sell	31,184 -6,736	-18%	-$177K	0.02%	599
2017 Q4	$1.02M	Buy	37,920 +13,382	+55%	+$340K	0.03%	539
2017 Q3	$591K	Sell	24,538 -3,332	-12%	-$75.3K	0.02%	729
2017 Q2	$598K	Sell	27,870 -20,734	-43%	-$418K	0.02%	712
2017 Q1	$833K	Buy	48,604 +17,882	+58%	+$311K	0.03%	586
2016 Q4	$551K	Sell	30,722 -49,806	-62%	-$903K	0.02%	734
2016 Q3	$1.68M	Sell	80,528 -15,374	-16%	-$381K	0.07%	249
2016 Q2	$2.58M	Sell	95,902 -21,184	-18%	-$581K	0.12%	159
2016 Q1	$3.17M	Sell	117,086 -8,192	-7%	-$219K	0.14%	123
2015 Q4	$3.64M	Buy	125,278 +9,526	+8%	+$264K	0.17%	109
2015 Q3	$3.14M	Sell	115,752 -6,716	-5%	-$190K	0.27%	69
2015 Q2	$3.35M	Sell	122,468 -7,732	-6%	-$217K	0.17%	109
2015 Q1	$3.48M	Sell	130,200 -50,876	-28%	-$1.17M	0.08%	206
2014 Q4	$3.83M	Buy	181,076 +5,160	+3%	+$115K	0.23%	75
2014 Q3	$4.19M	Sell	175,916 -37,292	-17%	-$858K	0.27%	66
2014 Q2	$4.92M	Sell	213,208 -30,898	-13%	-$682K	0.32%	50
2014 Q1	$5.57M	Sell	244,106 -1,065,324	-81%	-$22.7M	0.47%	27
2013 Q4	$4.89M	Buy	1,309,430 +1,045,470	+396%	+$18.2M	0.49%	29
2013 Q3	$4.47M	Sell	263,960 -5,270	-2%	-$88.6K	0.53%	27
2013 Q2	$4.17M	Buy	+269,230	New	+$4.48M	0.55%	23

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

FDx Advisors's NVO Position: Q1 2026 in Review

FDx Advisors sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 6,017 shares — an estimated $306K sold.

FDx Advisors first reported a position in NVO in Q2 2013 and held it in 50 quarters. The position peaked at $6.9M in Q1 2022. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

FDx Advisors reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
FDx Advisors sold 6,017 Novo Nordisk shares in Q1 2026, an estimated $306K.
FDx Advisors first reported a position in Novo Nordisk in Q2 2013 and held it in 50 quarters.
FDx Advisors's Novo Nordisk position peaked at $6.9M in Q1 2022.
1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on FDx Advisors's 13F filing for Q1 2026, filed 1 May 2026.